November 14th 2024
A new BLA for datopotamab deruxtecan aims for FDA accelerated approval to treat EGFR-mutated NSCLC based on data from multiple TROPION trials, following FDA feedback.
42nd Annual CFS: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Annual Hawaii Cancer Conference
January 25-26, 2025
Register Now!
41st Annual CFS®: Innovative Cancer Therapy for Tomorrow
View More
Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care
View More
Differentiating Adverse Events for Antibody-Drug Conjugates Across Solid Tumor Management
View More
Synergy of Radiotherapy and Anti-PD-1 Therapy With Pembrolizumab in NSCLC: Is This Perfect Harmony?
August 23rd 2017The investigators discuss their findings that demonstrate patients with previous radiotherapy experienced significantly longer PFS and OS with pembrolizumab treatment versus those with no previous radiotherapy.
Read More
Phase II Results for Cabozantinib in RET-Rearranged Lung Cancer
August 14th 2017Christine M. Lovly, MD, PhD, assistant professor of medicine (hematology/oncology), assistant professor of cancer biology, medical oncologist, Vanderbilt-Ingram Cancer Center, discusses phase II results for cabozantinib (Cabometyx) in patients with RET-rearranged lung cancer.
Watch
Combinations, Biomarkers Will Be Future Focus in Metastatic NSCLC, Expert Says
August 8th 2017Roy S. Herbst, MD, PhD, discusses how the therapeutic paradigm will continue to evolve in the next few years for non–small cell lung cancer, with an increased emphasis on rational combinations and biomarkers.
Read More
Frontline Alectinib Receives FDA's Priority Review for ALK-Positive NSCLC
August 4th 2017A supplemental new drug application (sNDA) for alectinib (Alecensa) has been granted a priority review by the FDA for the frontline treatment of patients with <em>ALK</em>-positive locally advanced or metastatic non–small cell lung cancer (NSCLC), according to Genentech (Roche), the manufacturer of the second-generation ALK inhibitor.
Read More
Durvalumab Granted Breakthrough Therapy Designation by FDA for NSCLC
July 31st 2017Durvalumab (Imfinzi) has been granted a breakthrough therapy designation by the FDA to treat patients with locally-advanced, unresectable non-small cell lung cancer (NSCLC) whose disease has not progressed following platinum-based chemoradiation.
Read More
Durvalumab/Tremelimumab Combo Fails to Improve PFS in Phase III NSCLC Trial
July 28th 2017Progression-free survival (PFS) was not improved with frontline durvalumab (Imfinzi), either in combination with tremelimumab or as a single agent, in patients with stage IV metastatic non–small cell lung cancer (NSCLC), compared with standard platinum-based chemotherapy.
Read More
Supplemental BLA for New Nivolumab Dosing Schedule Accepted by FDA
July 27th 2017Supplemental Biologics License Applications (sBLAs) were sent to and accepted by the FDA for a new dosing schedule for nivolumab (Opdivo) across all of the agent's indications as a montherapy, according to Bristol-Myers Squibb (BMS), the manufacturer of the PD-1 inhibitor.
Read More
Atezolizumab Moves to EU for Final Approval in Urothelial Carcinoma, NSCLC
July 24th 2017The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has given its support on indications for atezolizumab (Tecentriq) in non–small cell lung cancer (NSCLC) and urothelial carcinoma.
Read More